ERBB2 and breast cancer: Our group has previously shown that acute Her2 downregulation results in a rapid decrease in fluorodeoxyglucose ([18F]-FDG) uptake in Positron Emission Tomography (PET) in vivo in mammary tumors, immediately following treatment, irrespective of the baseline FDG uptake in the primary tumors29.